Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Zymeworks Inc. (NYSE: ZYME).

Full DD Report for ZYME

You must become a subscriber to view this report.


Recent News from (NYSE: ZYME)

Zymeworks presents IND-enabling data of ZW49 at the San Antonio Breast Cancer Symposium
Zymeworks (NYSE: ZYME ) presents IND-enabling data for ZW49, a biparatopic HER2-targeted antibody-drug conjugates (ADC), at the San Antonio Breast Cancer Symposium in San Antonio, TX. More news on: Zymeworks, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: December, 10 2018 07:24
Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium
ZW49 combines Azymetric™ and ZymeLink™ technologies to broaden the therapeutic window of antibody-drug conjugates (ADCs) Complete tumor regressions observed in high and low HER2-expressing models Superior preclinical efficacy compared to approved HER2 ADCs ...
Source: Business Wire
Date: December, 08 2018 08:00
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Deals and Financings BeiGene (BGNE) (HKEX:06160) of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks (ZYME) (see story ). BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispe...
Source: SeekingAlpha
Date: December, 02 2018 10:41
Zymeworks to Present at Upcoming Investor Conferences
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2...
Source: Business Wire
Date: November, 07 2018 16:30
Zymeworks reports Q3 results
Zymeworks (NYSE: ZYME ): Q3 GAAP EPS of -$0.59. More news on: Zymeworks, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 06 2018 16:59
Zymeworks Reports Financial Results for the Third Quarter of 2018
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2018. “We continue to expand our business with our seventh pharmaceutical partner, LEO Ph...
Source: Business Wire
Date: November, 06 2018 16:30
Zymeworks Announces Selection of ZW25 Abstract for Plenary Session Presentation at the 30th EORTC-NCI-AACR Symposium
Results from Phase 1 trial highlight ZW25’s single agent effect in HER2-driven cancers New and updated data focus on gastroesophageal and other HER2-expressing cancers Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunction...
Source: Business Wire
Date: October, 30 2018 06:45
Zymeworks teams up with LEO Pharma in bispecific antibodies
Zymeworks ( ZYME -1.9% ) will collaborate with Danish outfit LEO Pharma A/S to discover and develop bispecific antibodies, leveraging ZYME's Azymetric and EFECT platforms, for potential indications in dermatology, inflammation and autoimmune disorders. More news on: Zymeworks, Healthca...
Source: SeekingAlpha
Date: October, 23 2018 09:45
Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration
The companies will collaborate on the discovery of novel monospecific antibodies to develop bispecific therapeutics targeting cytokine-receptor pathways with applications in dermatology, inflammation, and autoimmunity by leveraging Zymeworks’ Azymetric™ and EFECT™ the...
Source: Business Wire
Date: October, 23 2018 06:45
Zymeworks (ZYME) Investor Presentation - Slideshow
The following slide deck was published by Zymeworks in conjunction with this Read more ...
Source: SeekingAlpha
Date: October, 12 2018 11:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1414.3414.3414.4814.10195,264

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-131,4058,80715.9532Cover
2018-12-123,14419,05616.4987Cover
2018-12-115,35626,15320.4795Cover
2018-12-1012,39928,73743.1465Short
2018-12-074,3117,09160.7954Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ZYME.


About Zymeworks Inc. (NYSE: ZYME)

Logo for Zymeworks Inc. (NYSE: ZYME)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NYSE: ZYME)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: September, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 29 2018
      Voluntary supplemental materials filed by foreign issuers under Section 11(a) of the 1933 Act
      Filing Type: SUPPLFiling Source: edgar
      Filing Date: August, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 02 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 01 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 01 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: July, 16 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: June, 19 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: June, 14 2018
      Post-effective amendment to an S-8 filing
      Filing Type: S-8 POSFiling Source: edgar
      Filing Date: June, 11 2018

       

       


      Daily Technical Chart for (NYSE: ZYME)

      Daily Technical Chart for (NYSE: ZYME)


      Stay tuned for daily updates and more on (NYSE: ZYME)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NYSE: ZYME)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ZYME is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ZYME and does not buy, sell, or trade any shares of ZYME. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/